Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis PatientsMaristella Pitzalis, Francesco Cucca, Lorena Lorefice et al.|Frontiers in Immunology|2021Cited by 57
Effect of different disease-modifying therapies on humoral response to BNT162b2 vaccine in Sardinian multiple sclerosis patientsMaristella Pitzalis, Francesco Cucca, Maria Laura Idda et al.|medRxiv|2021Cited by 6
Cross-sectional analysis of the humoral response after SARS-CoV-2 vaccination in Sardinian multiple sclerosis patients, a follow-up studyMaria Laura Idda, Francesco Cucca, Maristella Pitzalis et al.|Frontiers in Immunology|2022Cited by 6
Implications of disease-modifying therapies for multiple sclerosis on immune cells and response to COVID-19 vaccinationValeria Orrù, Francesco Cucca, Valentina Serra et al.|Frontiers in Immunology|2024Cited by 4
Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE)Piero Barbanti, Giacomo Querzola, Giulia Fiorentini et al.|The Journal of Headache and Pain|2025Cited by 4